Related Experiment Videos
Cognitive function in breast cancer patients receiving adjuvant chemotherapy
C B Brezden1, K A Phillips, M Abdolell
1Department of Medical Oncology and Hematology, Department of Biostatistics, Department of Psychosocial Oncology, Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada.
Summary
Breast cancer patients undergoing chemotherapy experience cognitive impairments, including issues with memory and concentration, compared to healthy individuals. These cognitive deficits are not linked to mood disturbances.
Area of Science:
- Oncology
- Neuroscience
- Psychology
Background:
- Chemotherapy is a critical treatment for breast cancer.
- Patients often report cognitive deficits, commonly termed 'chemobrain'.
Purpose of the Study:
- To investigate cognitive function differences in breast cancer patients receiving adjuvant chemotherapy versus healthy controls.
- To determine if mood disturbances contribute to observed cognitive changes.
Main Methods:
- Assessed cognitive function using the High Sensitivity Cognitive Screen.
- Evaluated mood with the Profile of Mood States (POMS).
- Compared 31 breast cancer patients on chemotherapy, 40 post-chemotherapy, and 36 healthy controls.
Main Results:
- Patients receiving chemotherapy showed significantly poorer cognitive function than healthy controls.
- Cognitive impairment was more prevalent in both chemotherapy and post-chemotherapy groups compared to controls.
- No significant mood differences were found between groups, suggesting mood is not the primary cause of cognitive changes.
Conclusions:
- Adjuvant chemotherapy is associated with cognitive differences in breast cancer patients.
- Observed cognitive deficits are likely treatment-related, not solely due to mood.
- Findings highlight the need for improved patient counseling and psychosocial support.